The characterization and application of a novel chemical degrader of NSD2 for the development of anti-cancer therapeutics

NSD2 新型化学降解剂的表征和应用，用于开发抗癌疗法

• 批准号: 476236
• 负责人: Nie David Y
• 金额: $ 7.65万
• 依托单位: University Health Network (Toronto)
• 依托单位国家: 加拿大
• 项目类别: Studentship Programs
• 财政年份: 2022
• 资助国家: 加拿大
• 起止时间: 2022-11-01 至 2025-11-01
• 项目状态: 未结题
• 来源: https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=476236&lang=en
• 关键词: Bioid; Cancer Epigenetics; Chemical Probe; Drug Design; Drug Technology; Epigenomics; Histone Methyltransferase; Nsd2; Protac; Targeted Protein Degradation

In cells, epigenetics can regulate DNA, the genetic codes of a cell, through alterations to the histone proteins, allowing DNA to unwind to be 'read' or compact to be 'silent.' Targeting this process is becoming an increasingly popular approach for cancer

在细胞中，表观遗传学可以通过改变组蛋白来调节DNA，也就是细胞的遗传密码，从而使DNA解体，使其被“读”或压缩成“沉默”。针对这一过程正在成为治疗癌症的一种越来越受欢迎的方法